Global Pigmentation Disorders Treatment Market - Snapshot
Pigmentation disorders include a large number of heterogeneous conditions that are usually characterized by altered melanocyte density, melanin concentration, or both, and result in altered pigmentation of the skin. Pigmentation disorders are of three types: hypopigmentation, depigmentation, or hyperpigmentation. Areas where pigmentation appears may be focal or diffuse. In hypopigmentation, pigments are decreased, whereas in depigmentation, pigments are completely lost, leaving the skin white. The most common disorders are melasma (hyperpigmentary) and vitiligo (hypopigmentary). The global pigmentation disorders treatment market was valued at around US$ 5,225 Mn in 2017 and is anticipated to expand at a CAGR of more than 6.8% from 2018 to 2026 to reach around US$ 9,268.6 Mn in 2026. Several factors such as augmented adoption of lasers in pigmentation disorders treatment, decrease in social taboos boosting acceptance of pigmentation disorders treatment measures, and increase in prevalence of pigmentation-related disorders are driving the global pigmentation disorders treatment market.
After stringent restructuring of regulations against dermo-cosmetic products and services, companies have started focussing on efficacy and quality with high investments in R&D. This has ultimately helped boost technological development and emergence of new products, services, and devices in the pigmentation disorder treatment market. The products and services have been moderated by regulatory bodies and have minimal side effects.
Opportunities for introducing new products, services, and devices are high as the market consists of established players and their brands. However, the market is still in search of highly efficient products and portable and technologically advanced devices. Safety and efficacy are major concerns in the pigmentation disorders treatment market. Therefore, introduction of such products presents a window of opportunity for new players to enter the market and establish themselves. The appreciation of regulatory compliance is a major factor that contributes to the success or failure of treatments, thus affecting sales. Galderma launched the triple combination to improve compliance of its key product, Tri-luma. Increased patient and provider awareness is also likely to help increase patient share of many marketed therapies during the forecast period.
The pigmentation disorder treatment market has been segmented based on treatment, disease indication, end-user, and region. In terms of treatment, the topical drugs segment is estimated to account for a prominent share of the market. An increasing number of patients with pigmentation disorders are visiting dermatologists, and topical drugs are being prescribed to these patients. With an existing unmet need for better treatment armamentarium for severe, recalcitrant patients and an estimated drug-treated population that is expected to double over the next decade, topical drugs is an attractive segment for drug developers. This is expected to fuel commercial interest in the development of tropical drugs.
Based on disease indication, the vitiligo and melasma segment constituted a major share of the market in 2017. The segment is likely to expand at a significant growth rate as compared to other disease indication segments during the forecast period. Globally, the prevalence of vitiligo and melasma varies. Women are far more likely to be affected by melisma than men, and both sexes are affected equally by vitiligo. In pigmentation, inadequate patient compliance still remains a significant unmet need. This single factor has hindered the ability of patients to achieve maximum treatment benefit, given the therapeutic options currently available, and has resulted in multiple failed treatment attempts.
In terms of region, the global pigmentation disorder treatment market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The pigmentation disorders treatment market is dominated by Asia Pacific. The market in the region is likely gain market share and expand at a rapid pace during the forecast period. The market in Asia Pacific is likely to be boosted by an increase in population, awareness about pigmentation disorder treatments and products, and growing economies. Furthermore, the pigmentation disorder treatment market in emerging economies of the Middle East, Latin America, and Africa is anticipated to add to the growth of the global market.
Prominent players in the global pigmentation disorder treatment market include Bayer AG, ALLERGAN, Galderma S.A., SkinCeuticals, Pierre Fabre, EpiPharm AG, RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC, and Vivier Pharma. The prevalent trend in the market is the strategic acquisition of key dermatology products by Big Pharma. A notable event in 2009 involved the acquisition of Stiefel, a leading dermatology company, by GSK for US$ 3.6 Bn.
Global Pigmentation Disorders Treatment Market: Overview
This report analyzes the global pigmentation disorders treatment market in terms of its current and future scenario. Rise in investment in R&D of novel advanced technologies, decrease in social taboos regarding pigmentation, increase in prevalence of pigmentation-related disorders, and rise in awareness about skin rejuvenation and treatment options are likely to drive the expansion of the global market during the forecast period. Pigmentation therapies can be classified as topical drugs, microdermabrasion, chemical peels, phototherapy, and laser therapy. These therapies are available in hospitals and aesthetic clinics & dermatology centers.
This report on the global pigmentation disorders treatment market comprises an elaborate executive summary, including a market snapshot that provides information about various segments of the market. The report also provides information and data analysis of the global market with respect to its segments based on product, application, and geography. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. In addition, the section comprises a competitive matrix and company profiles with a business overview to project the competitive landscape of the market. It also provides market attractiveness analysis in terms of geography and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the global pigmentation disorders treatment market.
Global Pigmentation Disorders Treatment Market: Key Segments
Based on treatment, the global pigmentation disorders treatment market has been segmented into topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others. In terms of disease indication, the market has been classified into hyperpigmentation (melasma, post-inflammatory hyperpigmentation, solar lentigines, and others) and hypopigmentation (vitiligo, albinism, and others). Based on end-user, the market has been categorized into hospitals, aesthetic clinics & dermatology centers, and others. The global pigmentation disorders treatment market has been analyzed based on increase in prevalence of pigmentation disorders, technology trends, expenditure on emerging technologies, and presence of key players in the region. Market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGR for the forecast period from 2018 to 2026, considering 2017 as the base year.
Global Pigmentation Disorders Treatment Market: Regional Outlook
In terms of geography, the global pigmentation disorders treatment market has been categorized into five major regions and key countries in these regions: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC, South Africa, Israel, and Rest of Middle East & Africa). Market size and forecast for each of these regions and their key countries have been provided for the period of 2016 to 2026, along with their respective CAGR for the forecast period from 2018 to 2026, considering 2017 as the base year. This report also covers the competitive scenario of the market in these regions.
Companies Mentioned in Report
The report profiles major players operating in the global pigmentation disorders treatment market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in this report are Bayer AG, ALLERGAN, Galderma S.A., SkinCeuticals, Pierre Fabre, EpiPharm AG, RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC, and Vivier Pharma.
The global pigmentation disorders treatment market has been segmented as follows:
Pigmentation Disorders Treatment Market, by Treatment
- Topical Drugs
- Laser Therapy
- Chemical Peels
Pigmentation Disorders Treatment Market, by Disease Indication
- Post-inflammatory Hyperpigmentation
- Solar Lentigines
Pigmentation Disorders Treatment Market, by End-user
- Aesthetic Clinics & Dermatology Centers
Pigmentation Disorders Treatment Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa